Connect your AI

ImmunityBio, Inc. IBRX Intangibles (Net)

Intangibles (Net) at other companies

IncyteINCY

$110.16M+2.4%

AmgenAMGN

$20.67B-16.2%

Eli LillyLLY

$7.37B+22.7%

ModernaMRNA

——

Other financials

Income statement

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s intangibles (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ImmunityBio, Inc.'s intangibles (net)?: ImmunityBio, Inc. (IBRX) reported intangibles (net) of $11.91M in Q1 2026.
How has ImmunityBio, Inc.'s intangibles (net) changed year-over-year?: ImmunityBio, Inc.'s intangibles (net) decreased by 15.0% year-over-year, from $14.02M to $11.91M.
What is the long-term trend for ImmunityBio, Inc.'s intangibles (net)?: Over 4 years (2020 to 2025), ImmunityBio, Inc.'s intangibles (net) has grown at a 72.6% compound annual growth rate (CAGR), from $1.46M to $12.99M.
What does intangibles (net) mean?: Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.